Key insights
- Lilly Endowment sold $15.75M of LLY stock. LLY is investing $4.5B in Indiana sites, bringing total investment to $21B since 2020. Omvoh showed sustained remission in ulcerative colitis patients over four years. LLY declared a $1.73 quarterly dividend. RBC Capital reiterated an Outperform rating, while Goldman Sachs maintained a Buy rating. The Endowment sale and potential liver safety concerns (implied by analyst commentary) exert slight negative pressure.
Indianapolis — Lilly Endowment Inc. reported the sale of 15,828 shares of Eli Lilly & Co. (NYSE:LLY) common stock on May 6, 2026, according to a recent SEC Form 4 filing. The transactions totaled approximately $15.75 million.
The shares were sold in multiple transactions at prices ranging from $995.00 to $996.46 per share. Specifically, 13,620 shares were sold at a weighted average price of $995.225, with individual transaction prices between $995.00 and $995.9963. An additional 2,208 shares were sold at a weighted average price of $996.183, with prices ranging from $996.00 to $996.46.The pharmaceutical giant, with a market capitalization of $867.66 billion, trades at a P/E ratio of 34.76 while delivering impressive revenue growth of 47% in the last twelve months as of Q1 2026.
Following these sales, Lilly Endowment Inc. directly holds 91,881,150 shares of Eli Lilly & Co. common stock. The endowment is identified in the filing as a former 10% shareholder of the pharmaceutical company.
In other recent news, Eli Lilly and Company announced a substantial $4.5 billion investment in its Lebanon, Indiana sites, enhancing its total capital commitments in the state to over $21 billion since 2020. This investment will aid the development of Lilly Lebanon API and the company’s first genetic medicine manufacturing facility, Lilly Lebanon Advanced Therapies. Additionally, Eli Lilly reported that patients with ulcerative colitis treated with Omvoh maintained disease clearance over four years in a study, with 63.5% of patients sustaining remission. The company also declared a quarterly dividend of $1.73 per share for the second quarter of 2026, payable on June 10 to shareholders of record by May 15.
In analyst ratings, RBC Capital reiterated an Outperform rating on Eli Lilly, citing liver safety data that aligns with clinical trial results. Similarly, Goldman Sachs maintained a Buy rating on Eli Lilly stock, despite a report in the FDA Adverse Event Reporting System about a patient experiencing hepatic failure after using Foundayo. These developments reflect ongoing confidence from analysts in Eli Lilly’s market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.